Neumora Therapeutics IPO Presentation Deck

NMRA-CK18 for Amyotrophic Lateral Sclerosis Pharmacology - Focused on inhibiting the protein casein kinase-16 (CK18) to reduce levels of the pathological form of TDP-43 and slow disease progression in ALS - CK16 also regulates tau biology which may enable indication expansion Epidemiology -5,000 people diagnosed in U.S. each year and ~16,000 patients in U.S. live with ALS at a given time¹ Status Discovery stage; identified compounds demonstrating CK10 selectivity, nanomolar potency, and properties consistent with favorable CNS penetration Strong IP Protection Expect exclusivity through 2043+, based on composition of matter protection plus potential for patent term extension 1) CDC.gov, 2018. Strong Biological Rationale CK18 phosphorylates TDP-43, a key driver of TDP-43-driven pathology in ALS ALS PATHOLOGY Motor neuron Cytoplasm Nucleus CK18 O-ATP TDP-43 NMRA- CK18 Inhibits CK18 to reduce levels of pathological TDP-43 Phosphorylation TDP-43 aggregation can promote neurodegeneration Toxic TDP-43 aggregates Endogenous pathways. Enhanced in disease Drug impact Confidential 22

View entire presentation